No trading signal from this filing, it is purely a schedule announcement. The Q2 2026 earnings release on August 12 will be the next catalyst; monitor for revenue and adjusted EBITDA performance relative to the company's 2026 guidance ($200-205M revenue, $50-53M adjusted EBITDA per the 20-F).
Drugs in focus
KMDA drug pipeline →CYTOGAM
● Neutral Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already FDA-approved and commercially marketed
- Next catalyst
- None dated
What to watchCYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 5 $7.18entry
- T+1 · 3mo ago −0.56%α −0.40% · $7.14
- T+5 · 3mo ago −4.18%α −4.53% · $6.88
- T+20 · 3mo ago +16.99%α +17.59% · $8.40
- T+60 · 19d ago +10.03%α +9.84% · $7.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kamada filed a Form 6-K solely to announce the date of its Q2 and first-half 2026 financial results release (August 12, 2026) and provide conference call details. No financial results, guidance updates, or material business developments were included in this filing.
Key Facts
- Kamada will release Q2 and first-half 2026 financial results on August 12, 2026, before U.S. market open.
- Company will host a conference call at 8:30am ET on August 12 (dial-in and webcast provided).
- No interim financial figures or guidance revisions were disclosed in this filing.
Financial Impact
None, this filing contains no financial results or forward-looking updates.
Risk Factors
- Earnings release date announcement implies no material news or pre-announcement, but results could still surprise.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-085387 |
| Document: ea030058401ex99-1.htm | 0001213900-26-085387 |
| Document: 0001213900-26-085387-index-headers.html | 0001213900-26-085387 |
| Document: 0001213900-26-085387-index.html | 0001213900-26-085387 |
| Document: 0001213900-26-085387.txt | 0001213900-26-085387 |
Track record
25 reports on KMDA
8 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers